About Hexagon Bio
Hexagon Bio specializes in discovering and developing new medicines using synthetic biology and data science. They analyze genomic data from various species to identify small molecule inhibitors that target proteins involved in diseases like cancer. Their unique platform allows for rapid production of lead compounds, enabling faster clinical development compared to traditional methods. The company's goal is to create effective treatments for complex diseases and license their drug candidates to larger pharmaceutical companies.
Menlo Park, CaliforniaHeadquarters
2016Year Founded
$178.6MTotal Funding
LATE_VCCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees
Benefits
Flexible Work Hours
Gym Membership
Risks
Faces competition from biotech companies like Insitro and Recursion Pharmaceuticals.
Requires continuous updates to their platform due to rapid technological advancements.
Relies on external funding, posing financial risks if future funding is scarce.
Differentiation
Hexagon Bio uses synthetic biology to discover drugs from fungal genomes.
Their proprietary platform combines data science and synthetic biology for drug discovery.
Hexagon Bio's team includes experts in computational biology, biochemistry, and software engineering.
Upsides
Raised $77.3 million in Series B financing to expand their discovery platform.
Leverages reduced DNA sequencing costs to access vast genomic data.
Partnerships in AI and machine learning enhance drug discovery efficiency.
Funding
Total raised$178.59 M
Latest valuation$336.50 M
StageLATE_VC
LATE VC
9/30/2022$67
$336.50 MEARLY VC
8/31/2021$61
$305.00 MSERIES A
8/31/2020$47
$235.00 MSEED
5/31/2017$8
$41.50 M